Fate Therapeutics, Inc. (NASDAQ: FATE)
$1.7400
-0.0100 ( -2.41% ) 16.4K
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Market Data
Open
$1.7400
Previous close
$1.7500
Volume
16.4K
Market cap
$199.32M
Day range
$1.7460 - $1.9050
52 week range
$1.5500 - $8.8300
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Jul 31, 2024 |
4 | Insider transactions | 1 | Jul 31, 2024 |
4 | Insider transactions | 1 | Jul 31, 2024 |
4 | Insider transactions | 1 | Jul 31, 2024 |
3 | Insider transactions | 2 | Jul 31, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 11, 2024 |
def | Proxies and info statements | 20 | Apr 26, 2024 |
ars | Annual reports | 1 | Apr 26, 2024 |